MedTrace Logo

Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis

NCT04136262 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2022-03-22

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blinded, controlled trial with two parallel arms. The aim of the study is to evaluate whether Tripterygium wilfordii Hook F combined with methotrexate (MTX) might be better than MTX alone for postmenopausal women with active rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

Tripterygium wilfordii Hook F (TwHF)

Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.

DRUG

Methotrexate

Oral methotrexate 10 mg per week for 24 weeks.

OTHER

Dummy Tripterygium wilfordii Hook F (TwHF)

Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.

Sponsors & Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Quan Jiang, M.D · Guang' anmen hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-25
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136262 on ClinicalTrials.gov